However, SCLC cell lines have a range of sensitivities to the WEE1 inhibitor adavosertib [175], and clinical trials of adavosertib as a monotherapy show minimal efficacy in SCLC [73,81]. This evidence concerns the gene WEE1 and small cell lung carcinoma.